Clinical Data (Mino-Lok®)

Citius Pharmaceuticals completed a Phase 2b study in December 2014. There were 90 patients in the study, with 30 patients in the active arm and 60 patients in a matched cohort for comparison. All patients were receiving treatment at M.D. Anderson Cancer Center for hematologic or solid tumor cancers.

Outstanding Comparative Results

Our Mino-Lok product salvaged 100% of CVCs, helping to cure all of the bacteremias with no serious adverse events, compared to an 18% serious adverse event rate in the matched cohort where patients had the infected CVCs removed and replaced with a new CVC.

The published manuscript can be downloaded here.

Mino-Lok Arm

Control Arm

Patients

N = 30

Percent

N=60

Percent

Bacteremia: Gram+

17*

57%

32

53%

Bacteremia: Gram –

14*

47%

28

47%

Microbiologic Eradication

30

100%

60

100%

Relapse

0

0%

3

5%

Complications

0

0%

8

13%

Serious Adverse Events

0

0%

6

10%

Overall Complication Rate

0

0%

11**

18%

* One polymicrobial patient had a Gram+ and a Gram– organism cultured
** Six patients had more than one complication